Kezar Life Sciences stockholders reject Say-on-Pay, approve reverse split authorization

Kezar Life Sciences, Inc.

Say-on-Pay advisory vote failed: 27.2M against vs 19.8M for.
Reverse stock split authorized (ratio 1:2 to 1:20) at Board's discretion.
Directors Christopher Kirk and John Fowler elected with >33M votes each.
KPMG ratified as independent auditor for FY2024 with overwhelming support.
Company will hold annual Say-on-Pay votes until 2030 after advisory vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.